Advertisement
Treatment of thoracic aortic disease, a PV condition, is expected towitness a surge over the next five years as manufacturers focus on developingaortic stent grafts specific to this indication. The thoracic aorta isextremely risky to treat surgically because of the high mortality associatedwith this procedure; thus, the availability of a minimally invasivealternative -- thoracic endovascular aortic repair (TEVAR)-- has garnered alot of attention among physicians and represents a significant opportunity formarket expansion. Next-generation thoracic stent grafts, and clinical trialssupporting their efficacy, will expand the treatable patient population,leading to growth in procedures in excess of 20% over the next five years.
Advertisement
Growth in carotid artery stenting procedures slowed to less than 5% peryear in 2007 due to a lack of conclusive data supporting the safety andefficacy of the procedure compared to surgical alternatives. Compounding thislack was the CMS decision to not expand reimbursement coverage to includeselect asymptomatic carotid artery disease patients. In early 2008, CMSdecided, however, to reexamine the expansion to reimbursement. If expandedreimbursement is approved, and the Carotid Revascularization Endarterectomyversus Stenting Trial (CREST) trial yields favorable results for stenting,carotid stenting growth could jump to greater than 20% before 2012.
"Our market forecasts present variable growth models," says StephanieLaBelle, Analyst at Millennium Research Group. "These models consider thepotential expansion of carotid stenting reimbursement, the completion ofCREST, a large randomized clinical study comparing the efficacy of carotidartery stenting versus carotid endarterectomy, and the release of post-marketcarotid stenting surveillance data. These forecasts are supported by a surveyof US physicians who rated expanded CMS reimbursement as the factor that wouldhave the largest impact on growth in carotid stenting procedures; the releaseof clinical trial data supporting carotid artery stenting was ratedsecond-most important."
The US Markets for Peripheral Vascular Devices 2008 report providescoverage of all key industry competitors, including Abbott Vascular,AngioDynamics, B. Braun, Boston Scientific, Cook Medical, Cordis, C. R. Bard,ev3, Medtronic, W. L. Gore, and Terumo, among others. Global coverage of thisreport includes Europe, Asia-Pacific, Latin America, Canada, and Japan.
About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources, Inc.company (www.DecisionResources.com), is the global authority on medicaltechnology market intelligence and a leading provider of strategic informationto the health care sector. Focused solely on the medical device,pharmaceutical, and biotechnology industries, the company provides its clientswith the benefits of its specialized industry expertise through publishedreports and customized consulting services.
All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.For more information, contact: Amy Krohn Millennium Research Group 416-364-7776 x101 [email protected]
SOURCE Millennium Research Group
